SCHEMBL1963698

SCHEMBL1963698

Cc1ccc(S(=O)(=O)O/C(=C\C2CCCC2)c2cc3cc(C(F)(F)F)cnc3n2S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 5/20 0.34
GAA P10253 3/20 0.34
LMNA P02545 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
ALOX5 P09917 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
NOD2 Q9HC29 1/20 0.33
NOD1 Q9Y239 1/20 0.33
KDM4E B2RXH2 2/20 0.32
USP2 O75604 1/20 0.32
HPGD P15428 1/20 0.32
PTGS2 P35354 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
CCR6 P51684 1/20 0.32
F2 P00734 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1963699 1.00 MEN1 (0.35) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL1962583 0.90 ALOX5 (0.36) MEN1KMT2AALDH1A1GAANPSR1
SCHEMBL1962581 0.90 ALOX5 (0.36) MEN1KMT2AALDH1A1GAANPSR1
SCHEMBL1960759 0.90 ALOX5 (0.35) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL1960760 0.90 ALOX5 (0.35) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL1961132 0.87 LMNA (0.36) MEN1KMT2AALDH1A1LMNANPSR1
SCHEMBL1960503 0.87 LMNA (0.36) MEN1KMT2AALDH1A1LMNANPSR1
SCHEMBL1960504 0.87 LMNA (0.36) MEN1KMT2AALDH1A1LMNANPSR1
SCHEMBL1963603 0.85 L3MBTL1 (0.39) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL1961211 0.85 L3MBTL1 (0.39) MEN1KMT2AALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 MEN1 2759/4885KMT2A 1524/4885ALDH1A1 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.